Research programme: anti CD44v6 chimeric antigen receptor T cell therapy - AGC Biologics
Alternative Names: CAR-CD44v6 immune gene therapy - MolMed; CAR-T CD44v6; CARCD44v6; Chimeric antigen receptor CD44v6 immune gene therapy - AGC BiologicsLatest Information Update: 28 Jun 2023
At a glance
- Originator Scientific Institute San Raffaele
- Developer AGC Biologics; Scientific Institute San Raffaele
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Acute myeloid leukaemia
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for preclinical development in Haematological-malignancies in Italy (IV)
- 19 Jan 2022 AGC Biologics terminates a phase I/II trial in Acute myeloid leukemia in Czechia republic and Italy (NCT04097301)
- 07 Sep 2019 MolMed plans the first-in-human phase I/IIa EURE-CART1 trial for Acute myeloid leukaemia and Multiple myeloma (In infants, In children, In adolescents, In adults, In the elderly, Second-line therapy or greater, Refractory metastatic disease) in Czech Republic (IV, Infusion) , (EudraCT2018-000813-19)